ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
US Tech 100
20,107.20
-0.10%
Dow Jones
43,408.47
0.32%
Brent Oil
73.89
1.44%
Bitcoin
97,854.96
3.69%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arvinas Inc (ARVN) Quote

Arvinas Inc

Arvinas Inc (ARVN)

NASDAQ
22.69
1.05
(4.85%)
Closed November 20 4:00PM
Delayed by 15 minutes
22.69
0.00
( 0.00% )
Pre Market: 7:00AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
22.69
Bid
22.00
Ask
24.99
Volume
-
0.00 Day's Range 0.00
20.28 52 Week Range 53.08
Market Cap
1.559B
Previous Close
22.69
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
560,587
Shares Outstanding
68,713,098
Dividend Yield
-
PE Ratio
-4.24
Earnings Per Share (EPS)
-5.35
Revenue
78.5M
Net Profit
-367.3M

About Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arvinas.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was $22.69. Over the last year, Arvinas shares have traded in a share price range of $ 20.28 to $ 53.08.

Arvinas currently has 68,713,098 shares outstanding. The market capitalization of Arvinas is $1.56 billion. Arvinas has a price to earnings ratio (PE ratio) of -4.24.

Ask ADVFN Intelligence (AI)

Arvinas (ARVN) Options Flow Summary

ARVN Options Flow

Overall Flow

Bearish

Net Premium

-1M

Calls / Puts

0.00%

Buys / Sells

33.33%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ARVN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

November 12 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 12 2024
Edgar (US Regulatory)

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

November 04 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

October 30 2024
Edgar (US Regulatory)

Form 8-K - Current report

October 30 2024
Edgar (US Regulatory)

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...

October 30 2024
GlobeNewswire Inc.

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

October 22 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

October 22 2024
Edgar (US Regulatory)

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

October 21 2024
GlobeNewswire Inc.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

August 29 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.56-10.138613861425.2525.7521.1780767122.82124227CS
4-3.95-14.827327327326.6429.610621.1771268025.79983072CS
12-3.45-13.198163733726.1429.610621.1756058725.58677692CS
26-10.1-30.80207380332.7937.3821.1769400826.90809655CS
521.346.2763466042221.3553.0820.2874318832.88802355CS
156-60.31-72.66265060248384.9613.5755472337.71780685CS
260-11.39-33.421361502334.08108.46513.5754149045.33612378CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 1.98
(102.04%)
16.34M
AKTSAkoustis Technologies Inc
$ 0.1321
(51.66%)
57.77M
PETWag Group Company
$ 0.303
(44.22%)
18.31M
ESGROEnstar Group Ltd
$ 28.00
(40.92%)
28
CCECCapital Clean Energy Carriers Corporation
$ 24.99
(34.72%)
11
WSBFWaterstone Financial Inc
$ 9.00
(-40.98%)
4
TRSTriMas Corporation
$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
$ 11.00
(-40.15%)
212
PYXSPyxis Oncology Inc
$ 2.43
(-36.39%)
209.56k
XNCRXencor Inc
$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
$ 0.1321
(51.66%)
57.77M
PETWag Group Company
$ 0.303
(44.22%)
18.31M
WORXSCWorx Corporation
$ 1.98
(102.04%)
16.34M
XTKGX3 Holdings Company Ltd
$ 0.0775
(-13.89%)
10.83M
CRKNCrown Electrokinetics Corporation
$ 0.9853
(25.41%)
5.59M

ARVN Discussion

View Posts
Monksdream Monksdream 2 months ago
ARVN at a bottom channel
👍️0
Monksdream Monksdream 9 months ago
ARVN new 52=week high
👍️0
Monksdream Monksdream 9 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 9 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 11 months ago
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 4 years ago
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 5 years ago
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 5 years ago
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 5 years ago
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 5 years ago
Possibly wall at 30.50
👍️0
G-lupo G-lupo 5 years ago
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 5 years ago
The offering:

8-k
👍️0
boo boo boo boo 5 years ago
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 5 years ago
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 5 years ago
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 5 years ago
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 5 years ago
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 5 years ago
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 years ago
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 years ago
What you mean IBD?
👍️0
boo boo boo boo 5 years ago
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 years ago
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 years ago
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 years ago
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 years ago
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 years ago
Fook R's!

EOM
👍️0
boo boo boo boo 5 years ago
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
ARVN
👍️0
G-lupo G-lupo 6 years ago
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 6 years ago
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0

Your Recent History

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved